Overview

A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO)

Status:
Completed

Trial end date:
2015-12-18

Target enrollment:

Participant gender:

Summary

The purpose of this study was to evaluate long term efficacy and safety of treatment with solifenacin succinate (the study drug) in children with neurogenic detrusor overactivity after multiple dose administration.

Phase:

Phase 3

Details

Lead Sponsor:

Astellas Pharma Europe B.V.

Treatments:

Solifenacin Succinate